Laëtitia Stefani

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 214 citations

Gortec 2014-01 Tpextreme, Neoadjuvant Therapy, Medicine +11

Geriatric Factors Predict Chemotherapy Feasibility: Ancillary Results of FFCD 2001-02 Phase III Study in First-Line Chemotherapy for Metastatic Colorectal Cancer in Elderly Patients

Thomas Aparicio, Jean–Louis Jouve, Laurent Teillet et al. · Journal of Clinical Oncology · 2013 · 213 citations · Full text

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet · 2019 · 125 citations

Breast Oncology, Oncology, Early Breast Cancer +6

Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial

Claire Falandry, B. Weber, Aude-Marie Savoye et al. · Annals of Oncology · 2013 · 119 citations

Geriatric Oncology, Oncology, Elderly Patients +9

Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001–02)

Thomas Aparicio, Sandrine Lavau‐Denès, Jean–Marc Phelip et al. · Annals of Oncology · 2015 · 104 citations · Full text

Elderly Patients, Gastrointestinal Oncology, Medicine +8